Dr Jeremy Chataway (UCL Institute of Neurology) is leading a phase 3 trial involving more than 1,000 people with multiple sclerosis (MS) to investigate whether simvastatin could become a treatment for the condition.
Read: The Guardian,
Watch: BBC Breakfast,
More: The Telegraph,
Daily Mail,
Express,
BBC Radio 5 '5 live Breakfast' (from 1 hr 50 mins)
Close
